Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
Status unconfirmed · Phase 2 · Has a placebo group
Conditions studied: NASH, NASH - Nonalcoholic Steatohepatitis, Type 2 Diabetes, Diabetes Type 2, Diabetes, Fatty Liver, Fatty Liver, Nonalcoholic, NAFLD
In brief
A randomized, multi-center study evaluating MET409 (50 mg) alone or in combination with empagliflozin (10 mg) for 12 weeks. Assignment to MET409 will be double-blind and placebo-controlled. Empagliflozin will be incorporated into two of the treatment arms in an open-label manner.
Key facts
- Study ID
- NCT04702490
- Run by
- Metacrine, Inc.
- People needed
- 120
- Starts
- 2020-12-15
- Expected to finish
- 2022-06-01
- Last updated by the study team
- 2021-06-01
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Metacrine Investigative Site — Fort Myers, Florida, United States
- Metacrine Investigative Site — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.